Cargando…
Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results
BACKGROUND: Pirfenidone was approved by the European Medicines Agency and introduced in most European countries in 2011 for treatment of idiopathic pulmonary fibrosis (IPF). OBJECTIVE: To describe the national Danish experiences of pirfenidone treatment for IPF during 30 months with respect to targe...
Autores principales: | Salih, Goran Nadir, Shaker, Saher Burhan, Madsen, Helle Dall, Bendstrup, Elisabeth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Co-Action Publishing
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5018656/ https://www.ncbi.nlm.nih.gov/pubmed/27616539 http://dx.doi.org/10.3402/ecrj.v3.32608 |
Ejemplares similares
-
Risk factors for diagnostic delay in idiopathic pulmonary fibrosis
por: Hoyer, Nils, et al.
Publicado: (2019) -
Responsiveness and minimal clinically important difference of SGRQ-I and K-BILD in idiopathic pulmonary fibrosis
por: Prior, Thomas Skovhus, et al.
Publicado: (2020) -
Validation of the King’s Brief Interstitial Lung Disease questionnaire in Idiopathic Pulmonary Fibrosis
por: Prior, Thomas Skovhus, et al.
Publicado: (2019) -
Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation
por: Maher, Toby M., et al.
Publicado: (2019) -
Pirfenidone treatment of idiopathic pulmonary fibrosis
por: Gan, Ye, et al.
Publicado: (2011)